CN116270945A - Granule for soothing heart and soothing nerves and preparation method thereof - Google Patents
Granule for soothing heart and soothing nerves and preparation method thereof Download PDFInfo
- Publication number
- CN116270945A CN116270945A CN202310383075.1A CN202310383075A CN116270945A CN 116270945 A CN116270945 A CN 116270945A CN 202310383075 A CN202310383075 A CN 202310383075A CN 116270945 A CN116270945 A CN 116270945A
- Authority
- CN
- China
- Prior art keywords
- soothing
- heart
- granule
- nerve
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 35
- 210000005036 nerve Anatomy 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 45
- 239000000654 additive Substances 0.000 claims abstract description 32
- 230000000996 additive effect Effects 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 17
- 241000202726 Bupleurum Species 0.000 claims abstract description 14
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 12
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 11
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 11
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract 3
- 238000003756 stirring Methods 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 33
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 13
- 240000001341 Reynoutria japonica Species 0.000 claims description 8
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 8
- 240000008866 Ziziphus nummularia Species 0.000 claims description 8
- 241000736199 Paeonia Species 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 4
- 241000213006 Angelica dahurica Species 0.000 claims description 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 241000218176 Corydalis Species 0.000 claims description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 4
- 240000000233 Melia azedarach Species 0.000 claims description 4
- 241001080798 Polygala tenuifolia Species 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 240000003243 Thuja occidentalis Species 0.000 claims description 3
- 235000008109 Thuja occidentalis Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 24
- 208000029078 coronary artery disease Diseases 0.000 abstract description 22
- 208000024891 symptom Diseases 0.000 abstract description 10
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000008451 emotion Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 206010002383 Angina Pectoris Diseases 0.000 description 15
- 241000244355 Ligusticum Species 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 6
- 241001106477 Paeoniaceae Species 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 241000212322 Levisticum officinale Species 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011337 individualized treatment Methods 0.000 description 2
- 239000001645 levisticum officinale Substances 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 235000003398 Curcuma aromatica Nutrition 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides heart soothing and nerve soothing granules and a preparation method thereof, and relates to a coronary heart disease treatment technology for depression. The heart-soothing nerve-soothing granule comprises main medicines and additive components, wherein the main medicines comprise the following components in parts by weight: bupleurum root: 10-15 g; radix paeoniae rubra: 12-18 g; white peony root: 12-18 g; ligusticum wallichii: 12-18 g; radix Curcumae: 8-12 g; semen Ziziphi Spinosae: 17-23 g; honey-fried licorice root: 3-8 g. The heart-soothing nerve-soothing granule provided by the invention can obviously improve depression symptoms, lighten bad emotion of a patient, keep good living habit, improve living quality, be beneficial to compliance of treatment of the patient, improve clinical curative effect of coronary heart disease treatment, shorten hospitalization time, reduce incidence of readmission, avoid excessive medical treatment, lighten economic burden of families of the patient, obviously reduce incidence of adverse reaction accompanied with coronary heart disease, have no toxic or side effect, and improve living quality of the patient.
Description
Technical Field
The invention relates to the technical field of treatment of coronary heart disease of depression, in particular to heart-soothing and nerve-soothing granules and a preparation method thereof.
Background
Coronary heart disease and angina pectoris are one of common diseases which seriously threaten human life, often accompany with oestrus disorder, and anxiety and depression are the most common, and a large number of evidence-based medicines prove that the depression is an independent risk factor for the onset and prognosis of the coronary heart disease, so that the recovery and prognosis of patients are seriously influenced, and the anti-depression treatment of patients with coronary heart disease and angina pectoris combined depression is particularly important although the interaction mechanism between the coronary heart disease and the angina pectoris is undefined.
Clinical standard: standard of treatment of coronary heart disease and angina pectoris: the effect is shown: the symptoms of the angina pectoris basically disappear; the resting electrocardiogram is recovered to be normal, and the exercise load test is changed to be negative, so that the effect is achieved: the symptoms are obviously improved, and the frequency of angina pectoris attacks is obviously reduced to more than 50% before treatment; resting electrocardiogram and exercise load test, the ST segment of electrocardiogram is recovered to be normal or the main lead T wave becomes shallower by more than 50%, and the test is ineffective: the symptoms are not obviously improved; electrocardiogram recovery does not meet the above criteria, worsening: frequent angina attacks or exacerbation of symptoms; electrocardiogram ST segment descends more than 0.05mV before treatment, T wave inversion deepens more than 50% or stands up to inversion.
Clinical researches show that the depression degree and the coronary artery disease degree are related, negative mood disorders such as depression are regulated through a nerve-body fluid-endocrine mechanism, a series of physiological and pathological changes are caused, excessive secretion of catecholamine, lipid metabolism disorder, procoagulant substances and angiotensin I (TXA 2) with strong vasoconstriction effect are released, the heart rate is accelerated, the blood pressure is increased, angina pectoris is promoted or aggravated, serious heart clinical events are induced, adverse consequences are caused, for the patients, the treatment of coronary heart disease and angina pectoris is often poor in effect, symptom improvement is slow, and the treatment of the emotional intervention is very necessary, so that the coronary heart disease and the depression are required to be treated simultaneously, obvious clinical curative effects can be obtained, the traditional Chinese medicine considers that the depression belongs to the category of depression, the symptoms caused by depression and qi stagnation, the qi stagnation are caused by the deficiency of excess, five viscera qi imbalance are caused, the liver is the heart, the body yin is used for treating yang, the liver qi stagnation is favored, the qi stagnation is caused, the depression is caused, the heart blood is easy, the mind is disturbed, and the qi is easy to reverse the qi is easy to treat the disorder, and the qi stagnation is easy to treat the coronary heart disease and the angina pectoris, the liver qi is calm and the qi is calm, and the qi is calm and the qi is soothing liver qi is soothing qi, and the qi is soothing particles are prepared.
Disclosure of Invention
(one) solving the technical problems
Aiming at the defects of the prior art, the invention provides heart soothing and nerve soothing granules and a preparation method thereof, and solves the problems that for patients suffering from depression and coronary heart disease at the same time, the degree of depression causes coronary artery disease to cause a series of physiological and pathological changes, angina is promoted or aggravated, serious heart clinical events are induced, and adverse effects are caused.
(II) technical scheme
In order to achieve the above purpose, the invention is realized by the following technical scheme: the heart soothing and nerve soothing granule comprises main medicines and additive components, wherein the main medicines comprise the following components in parts by weight:
bupleurum root: 10-15 g;
radix paeoniae rubra: 12-18 g;
white peony root: 12-18 g;
ligusticum wallichii: 12-18 g;
radix Curcumae: 8-12 g;
semen Ziziphi Spinosae: 17-23 g;
honey-fried licorice root: 3-8 g.
Preferably, the composition comprises the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g of honey-fried licorice root: 5g.
Preferably, the additive component comprises tuber fleeceflower stem: 12-18 g, arborvitae seed: 12-18 g and polygala tenuifolia: 10-15 g.
Preferably, the additive component further comprises chrysanthemum flower: 12-18 g, mother-of-pearl: 22-28 g and grassleaf sweelflag rhizome: 12-18 g.
Preferably, the additive component further comprises cortex Albiziae: 28-32 g, tuber fleeceflower stem: 18-22 g and Chinese angelica: 8-12 g.
Preferably, the additive component further comprises szechwan chinaberry fruit: 12-18 g, rhizoma corydalis: 10-15 g and angelica: 10-15 g.
Preferably, the preparation method of the heart-soothing and nerve-soothing granules comprises the following steps of:
step one: proportioning materials
Firstly, weighing and proportioning the main medicine and the additive components according to the weight components, and entering the first step and the second step;
step two: preparation of Main drug particles
Washing and drying the main medicine prepared in the first step, crushing by a crusher, pouring into a stirring tank for scattering and stirring, pouring into a granulator after stirring and mixing to prepare main medicine particles, and entering the fourth step;
step three: preparation of additive particles
Washing and drying the additive components prepared in the first step, crushing by a crusher, pouring into a stirring tank for scattering and stirring, pouring into a granulator after stirring and mixing to prepare additive particles, and entering the fourth step;
step four: packaging
And (3) respectively packaging the main medicine particles and the additive particles prepared in the step (III) and the step (IV) by a packer.
Preferably, in the second step, the particles of the main drug particles have a particle size of at least 0.4-0.7 cm, and the stirring speed of the stirring tank is as follows: 400-800 rpm, and the stirring time is as follows: 0.5 to 1.0h.
Preferably, in the third step, particles with particle sizes of at least 0.3-0.5 cm are added, and the stirring speed of the stirring tank is as follows: 400-550 rpm, and the stirring time is as follows: 0.5 to 1.0h.
(III) beneficial effects
The invention provides a heart-soothing and nerve-soothing granule and a preparation method thereof. The beneficial effects are as follows:
the heart-soothing nerve-soothing granule and the preparation method thereof provided by the invention can obviously improve depression symptoms, relieve bad emotion of patients, keep good living habit, improve living quality, facilitate compliance of treatment of the patients, improve clinical curative effect of coronary heart disease treatment, shorten hospitalization time, reduce incidence of readmission, avoid overtherapy, lighten economic burden of families of the patients, obviously reduce incidence of adverse reaction accompanied with coronary heart disease, have no toxic or side effect, and improve living quality of the patients. The decoction for soothing the heart and relieving depression is based on the dialectical theory of the traditional Chinese medicine, and the four diagnosis and the combination of the four diagnosis and the reasonable compatibility of medicines are adopted, so that the decoction mainly aims at soothing the liver and regulating qi, and meanwhile, the medicines are increased or decreased according to different conditions, so that an individualized treatment method is embodied.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The embodiment of the invention provides a heart-soothing and nerve-soothing granule.
As one aspect of the application, the invention provides a heart soothing and nerve soothing granule, which comprises main medicines and additive components, wherein the main medicines comprise the following components in parts by weight: bupleurum root: 10-15 g, red paeony root: 12-18 g, white peony root: 12-18 g, ligusticum wallichii: 12-18 g, radix curcumae: 8-12 g, wild jujube seed: 17-23 g, honey-fried licorice root: 3-8 g.
Wherein the white peony root nourishes blood and softens liver, the szechuan lovage rhizome and the turmeric root-tuber sooth liver and relieve depression, regulate qi and activate blood; semen Ziziphi Spinosae and caulis Polygoni Multiflori have effects of nourishing heart and tranquilizing, and rhizoma Ligustici Chuanxiong and radix Curcumae relieve smooth muscle spasm, reduce coronary artery resistance, and increase coronary blood flow; radix Paeoniae Rubra has effects of dilating coronary artery, resisting myocardial ischemia, resisting blood platelet aggregation, and resisting thrombosis, etc.: the medicines with the functions of promoting blood circulation and removing blood stasis such as ligusticum wallichii and radix curcumae inhibit platelet aggregation, reduce blood viscosity, enhance fibrinolytic activity and improve myocardial microcirculation, and researches show that the bupleurum, white paeony root, ligusticum wallichii and radix curcumae can promote 5-HT synthesis of cortical parts and inhibit 5-HT metabolism or reuptake. The main component of semen Ziziphi Spinosae contains semen Ziziphi Spinosae saponin for reducing dopamine and 3, 4-dihydroxyphenylacetic acid content to produce central tranquilizing effect.
The additive components comprise 12-18 g of tuber fleeceflower stem, 12-18 g of platycladi seed and 10-15 g of polygala tenuifolia.
The additive components also comprise 12-18 g of chrysanthemum, 22-28 g of mother-of-pearl and 12-18 g of grassleaf sweelflag rhizome.
The additive components also comprise 28-32 g of cortex albiziae, 18-22 g of tuber fleeceflower stem and 8-12 g of angelica.
The additive components also comprise 12-18 g of szechwan chinaberry fruit, 10-15 g of rhizoma corydalis and 10-15 g of Chinese angelica.
The heart soothing and nerve soothing granule provided by the invention is used by decocting soup in concentration, and taking 240-260 m l, taking the granule for warm taking in the morning and evening for 1 dose each day, wherein the period of treatment is 1 course of treatment for 4 weeks, so that a user can obviously improve depression symptoms, reduce bad mood of a patient, keep good life habit, improve life quality, be beneficial to patient treatment compliance, improve clinical curative effect of coronary heart disease treatment, shorten hospitalization time, reduce incidence of readmission, avoid excessive medical treatment, reduce economic burden of families of the patient, obviously reduce incidence of adverse reaction accompanied with coronary heart disease, have no toxic or side effect, improve life quality of the patient, and the heart soothing and nerve soothing granule is prepared according to the dialectical theory of traditional Chinese medicine, reasonably compatibility of medicines is adopted, and medicines are increased and decreased according to different conditions, so that an individualized treatment method is embodied.
As another aspect of the present application, the preparation method of the granule for soothing the heart and soothing the nerves comprises the following steps:
step one: proportioning materials
Firstly, weighing and proportioning the main medicine and the additive components according to the weight components, and entering the first step and the second step;
step two: preparation of Main drug particles
Washing and drying the main medicine prepared in the first step, crushing the main medicine by using a crusher, injecting the main medicine into a stirring tank for scattering and stirring, injecting the main medicine into a granulator after stirring and mixing to prepare main medicine particles, and feeding the main medicine particles into the fourth step, wherein the particle size of the main medicine particles is at least 0.4-0.7 cm, and the stirring speed of the stirring tank is as follows: 400-800 rpm, and the stirring time is as follows: 0.5 to 1.0h;
step three: preparation of additive particles
Washing and drying the additive components prepared in the first step, crushing by using a crusher, injecting into a stirring tank for scattering and stirring, injecting into a granulator after stirring and mixing to prepare additive particles, and entering into a fourth step, wherein the particle size of the additive particles is at least 0.3-0.5 cm, and the stirring speed of the stirring tank is as follows: 400-550 rpm, and the stirring time is as follows: 0.5 to 1.0h;
step four: packaging
And (3) respectively packaging the main medicine particles and the additive particles prepared in the step (III) and the step (IV) by a packer.
In order to better illustrate the formulation implementation scheme of the heart soothing and nerve soothing granule of the invention, the following is exemplified:
example 1:
on the basis of conventional treatment, the heart soothing and nerve soothing granules provided by the embodiment are subjected to decoction, and the heart soothing and nerve soothing granules consist of the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g of honey-fried licorice root: 5g, wherein the white paeony root nourishes blood and softens liver, the szechuan lovage rhizome and the turmeric root-tuber sooth liver and relieve depression, regulate qi and activate blood; semen Ziziphi Spinosae and caulis Polygoni Multiflori have effects of nourishing heart and tranquilizing, and rhizoma Ligustici Chuanxiong and radix Curcumae relieve smooth muscle spasm, reduce coronary artery resistance, and increase coronary blood flow; radix Paeoniae Rubra has effects of dilating coronary artery, resisting myocardial ischemia, resisting blood platelet aggregation, and resisting thrombosis, etc.: the medicines with the functions of promoting blood circulation and removing blood stasis such as ligusticum wallichii and radix curcumae inhibit platelet aggregation, reduce blood viscosity, enhance fibrinolytic activity and improve myocardial microcirculation, and researches show that the bupleurum, white paeony root, ligusticum wallichii and radix curcumae can promote 5-HT synthesis of cortical parts and inhibit 5-HT metabolism or reuptake. The main component of semen Ziziphi Spinosae, semen Ziziphi Spinosae saponin, can reduce the content of dopamine and 3, 4-dihydroxyphenylacetic acid to produce central sedation, and is taken orally in 2 times a day, 1 dose a day, and 1 course of treatment 4 weeks.
Example 2:
on the basis of the embodiment, the embodiment provides another heart soothing and nerve soothing granule for people with insomnia and dreaminess, which comprises the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g, honey-fried licorice root: 5g, tuber fleeceflower stem: 12-18 g, arborvitae seed: 12-18 g and polygala tenuifolia: 10-15 g, warm taken for 2 times in the morning and evening, 1 dose per day, and 1 treatment course for 4 weeks.
Example 3:
the embodiment is different from the above embodiment, and another granule for soothing the heart and soothing the nerves is provided for people with dizziness, and comprises the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g, honey-fried licorice root: 5g, adding chrysanthemum: 12-18 g, mother-of-pearl: 22-28 g and grassleaf sweelflag rhizome: 12-18 g, warm taken for 2 times in the morning and evening, 1 dose per day, and 1 treatment course for 4 weeks.
Example 4:
the embodiment is different from the above embodiment, and another granule for soothing the heart and soothing the nerves is provided for people with restlessness, and comprises the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g, honey-fried licorice root: 5g, cortex albiziae: 28-32 g, tuber fleeceflower stem: 18-22 g and Chinese angelica: 8-12 g, wherein cortex albiziae has the effects of resolving depression and soothing nerves, and also has the effect of activating blood, and is taken warm for 2 times in the morning and evening, 1 dose per day, and 1 treatment course is 4 weeks.
Example 5:
the above embodiments are distinguished, and another granule for soothing the heart and soothing the nerves is provided for people with pain-like discomfort on the body, which comprises the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g, honey-fried licorice root: 5g, szechwan chinaberry fruit: 12-18 g, rhizoma corydalis: 10-15 g and angelica: 10-15 g, warm taken for 2 times in the morning and evening, 1 dose per day, and 1 treatment course for 4 weeks.
Comparative example:
90 patients with coronary heart disease and angina pectoris accompanied by depression are randomly divided into 45 cases of a control group and a treatment group, 45 cases of the treatment group are represented by 22 cases of men, 23 cases of women, ages 38-58 years old, average 51 years old, 45 cases of the control group, 23 cases of men, 22 cases of women, ages 35-59 years old, average 52 years old, the control group is conventionally given with new treatments of isosorbide mononitrate, aspirin, atorvastatin and antidepressant drug Dali, the treatment group is orally taken with Shuxin tranquilization granule soup on the basis of the treatment of the control group, the total treatment is carried out for 4 weeks, the treatment is carried out regularly by adopting the score of the hamilton depression scale (HAMD),
the comparison of the two clinical effects is shown in tables 1-3
Table 1: comparison of two clinical efficacy (n)
Δ P<0.05。
Table 2: scoring comparison (score, x+ -s) of two sets of HAMD scales
| Group of | n | Before treatment | Treatment for 2 weeks | Treatment for 4 weeks |
| Treatment group | 45 | 29.80±4.13 | 22.44±4.56* | 19.23±4.33** |
| Control group | 45 | 28.97±4.43 | 24.04±4.47* Δ | 21.22±4.42* Δ |
P <0.05, P <0.01 compared to prior to treatment in this group; Δp <0.05, ΔΔp <0.01 compared to the control contemporaneous.
Table 3: comparison of adverse reactions of two groups n (%)
Studies have shown that depression is related to coronary lesions, negative mood disorders such as depression are mediated by neuro-humoral-endocrine mechanisms, triggering a series of physiological and pathological changes, excessive secretion of catecholamines, lipid metabolism disorders, procoagulant substances and angiotensin I (TXA 2) Release, heart rate acceleration, blood pressure elevation, etc., promote or aggravate angina pectoris, induce serious cardiac clinical events, and cause adverse effects. For patients of this type, the treatment of coronary heart disease and angina pectoris is often poor in effect, the symptom improvement is slow, and the emotional intervention treatment is necessary. Therefore, the coronary heart disease, angina pectoris and depression are treated simultaneously, so that obvious clinical curative effect can be achieved. The traditional Chinese medicine considers that the depression belongs to the category of depression in the traditional Chinese medicine, and is a disease caused by depression of emotion and qi stagnation, and the disorder of qi movement of five viscera is caused by excess and deficiency for a long time. Liver is just viscera, yin and yang, and happy with each other and dysthymia. The heart governs blood vessels and the heart spirit is not calm, so qi movement is easy to be disordered. The traditional Chinese medicine considers that the depression is treated firstly and the qi is regulated firstly and the liver is regulated firstly, so that the liver is regulated by soothing heart and relieving Yu Shangshu, the heart is calmed and the blood is nourished, the bupleurum root in the prescription is used for soothing liver and relieving depression, the radix curcumae is matched for entering blood, the red paeony root is used for activating blood and regulating liver, the qi is smoothened, the white paeony root is used for nourishing blood and softening liver, the ligusticum wallichii and the radix curcumae are used for soothing liver and relieving depression, and the qi is regulated and activated; semen Ziziphi Spinosae and caulis Polygoni Multiflori have effects of nourishing heart and tranquilizing; cortex Albiziae has effects of resolving stagnation, tranquilizing, and promoting blood circulation. Studies have shown that bupleuri radix, radix Paeoniae alba, rhizoma Ligustici Chuanxiong, and radix Curcumae can promote 5-HT synthesis at cortical site, inhibit 5-HT metabolism or reuptake. Semen Ziziphi Spinosae saponin as main ingredient can be used for lowering blood pressureLow dopamine and 3, 4-dihydroxyphenylacetic acid content to produce central sedation; ligusticum wallichii and curcuma aromatica relieve smooth muscle spasm, reduce coronary artery resistance, and increase coronary blood flow; radix Paeoniae Rubra has effects of dilating coronary artery, resisting myocardial ischemia, resisting blood platelet aggregation, and resisting thrombosis, etc.: blood circulation promoting and blood stasis removing medicines such as rhizoma Ligustici Chuanxiong and radix Curcumae can inhibit platelet aggregation, reduce blood viscosity, enhance fibrinolytic activity, and improve myocardial microcirculation.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (9)
1. A heart soothing and nerve soothing granule, which is characterized in that: the traditional Chinese medicine composition comprises main medicine and additive components, wherein the main medicine comprises the following components in parts by weight:
bupleurum root: 10-15 g;
radix paeoniae rubra: 12-18 g;
white peony root: 12-18 g;
ligusticum wallichii: 12-18 g;
radix Curcumae: 8-12 g;
semen Ziziphi Spinosae: 17-23 g;
honey-fried licorice root: 3-8 g.
2. The heart soothing and nerve soothing granule of claim 1, wherein: the composition comprises the following components in parts by weight: bupleurum root: 12g, red peony root: 15g, white peony root: 15g, ligusticum wallichii: 15g, radix curcumae: 10g, wild jujube seed: 20g of honey-fried licorice root: 5g.
3. The heart soothing and nerve soothing granule of claim 1, wherein: the additive components comprise tuber fleeceflower stems: 12-18 g, arborvitae seed: 12-18 g and polygala tenuifolia: 10-15 g.
4. The heart soothing and nerve soothing granule of claim 1, wherein: the additive components also comprise chrysanthemum: 12-18 g, mother-of-pearl: 22-28 g and grassleaf sweelflag rhizome: 12-18 g.
5. The heart soothing and nerve soothing granule of claim 1, wherein: the additive components also comprise cortex albiziae: 28-32 g, tuber fleeceflower stem: 18-22 g and Chinese angelica: 8-12 g.
6. The heart soothing and nerve soothing granule of claim 1, wherein: the additive components also comprise szechwan chinaberry fruit: 12-18 g, rhizoma corydalis: 10-15 g and angelica: 10-15 g.
7. A method for preparing a heart soothing and nerve soothing granule, using a heart soothing and nerve soothing granule according to any one of claims 1 to 6, characterized in that: the method comprises the following steps:
step one: proportioning materials
Firstly, weighing and proportioning the main medicine and the additive components according to the weight components, and entering the first step and the second step;
step two: preparation of Main drug particles
Washing and drying the main medicine prepared in the first step, crushing by a crusher, pouring into a stirring tank for scattering and stirring, pouring into a granulator after stirring and mixing to prepare main medicine particles, and entering the fourth step;
step three: preparation of additive particles
Washing and drying the additive components prepared in the first step, crushing by a crusher, pouring into a stirring tank for scattering and stirring, pouring into a granulator after stirring and mixing to prepare additive particles, and entering the fourth step;
step four: packaging
And (3) respectively packaging the main medicine particles and the additive particles prepared in the step (III) and the step (IV) by a packer.
8. The method for preparing the heart soothing and nerve soothing granules according to claim 1, which is characterized in that: in the second step, the particle size of the main medicine particles is at least 0.4-0.7 cm, and the stirring speed of the stirring tank is as follows: 400-800 rpm, and the stirring time is as follows: 0.5 to 1.0h.
9. The method for preparing the heart soothing and nerve soothing granules according to claim 1, which is characterized in that: in the third step, particles with particle sizes of at least 0.3-0.5 cm are added, and the stirring speed of the stirring tank is as follows: 400-550 rpm, and the stirring time is as follows: 0.5 to 1.0h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310383075.1A CN116270945A (en) | 2023-04-06 | 2023-04-06 | Granule for soothing heart and soothing nerves and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310383075.1A CN116270945A (en) | 2023-04-06 | 2023-04-06 | Granule for soothing heart and soothing nerves and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116270945A true CN116270945A (en) | 2023-06-23 |
Family
ID=86778209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310383075.1A Pending CN116270945A (en) | 2023-04-06 | 2023-04-06 | Granule for soothing heart and soothing nerves and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116270945A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845690A (en) * | 2012-12-09 | 2014-06-11 | 周年春 | Medicament for treating geriatric depression |
-
2023
- 2023-04-06 CN CN202310383075.1A patent/CN116270945A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845690A (en) * | 2012-12-09 | 2014-06-11 | 周年春 | Medicament for treating geriatric depression |
Non-Patent Citations (1)
| Title |
|---|
| 倪代梅等: ""舒心解郁汤治疗冠心病心绞痛合并抑郁症临床研究"", 《中国中医急症》, vol. 23, no. 05, pages 835 - 836 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115837065B (en) | Traditional Chinese medicine composition and application thereof | |
| CN115501304B (en) | Traditional Chinese medicine compound composition for treating heart-liver fire hyperactivity type insomnia and preparation method and application thereof | |
| CN114010751B9 (en) | Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue | |
| CN102847075B (en) | Medicine composition for treating insomnia | |
| CN103182022A (en) | Method for preparing traditional Chinese medicinal potus for preventing and treating subhealth condition | |
| CN103977281A (en) | Traditional Chinese medicine composition for treating female endocrine disorders and preparation method thereof | |
| CN115252753B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN102772611A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN117599125A (en) | A Chinese medicinal composition for supplementing calcium and strengthening bones for treating osteoporosis, and its preparation method and application | |
| CN116270945A (en) | Granule for soothing heart and soothing nerves and preparation method thereof | |
| CN104324134B (en) | One kind improves microcirculatory Chinese medicine composition and preparation method thereof | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN104435298A (en) | Anti-depression pharmaceutical composition | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN109602865B (en) | Traditional Chinese medicine composition for treating depression and pharmaceutical composition and application thereof | |
| CN104352973A (en) | Chinese patent medicine for postpartum depression | |
| CN117414351B (en) | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof | |
| CN111407868B (en) | Traditional Chinese medicine pill for improving cognitive function of brain | |
| CN107137651A (en) | It is a kind of to treat medicine of depression and preparation method thereof | |
| CN101569708B (en) | Medicament for treating ischemic heart disease and preparation method thereof | |
| CN101317903A (en) | Medicine for treating leucoderma and its preparation method | |
| CN105687600A (en) | Traditional Chinese medicine composition for treating climacteric syndrome, as well as preparation method and application thereof | |
| CN105770563A (en) | Traditional Chinese medicine preparation for treating anxiety disorder and preparation method for traditional Chinese medicine preparation | |
| CN104258301A (en) | Traditional Chinese medicine composition for treating female climacteric ventricular premature beat | |
| CN118340839A (en) | Heart-nourishing and vein-invigorating composition, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230623 |